Importantly, the combination of HDAC inhibitors and HSP90 inhibitors has synergistic effects in certain cancers, particularly leukemia, while antagonistic effects are seen in some solid tumors (Krämer et al., 2014; Chen et al., 2020). This evidence concerns the gene HSP90AB1 and cancer.